Special edition: Functional foods

Phood booed: Why big pharma fails at functional food

By Julian Mellentin

- Last updated on GMT

Mellentin: "If you want to see the future of functional food, look down at the small entrepreneurial brands..."
Mellentin: "If you want to see the future of functional food, look down at the small entrepreneurial brands..."

Related tags Nutrition Food

Faced with mounting difficulties in their drug businesses, many pharmaceutical manufacturers are looking at getting into functional foods and beverages, notes food marketing expert, Julian Mellentin in this guest article.

It’s not a new strategy. Many times already, 'big pharma' has focused on nutrition. And in almost all cases these forays have turned into disasters.

One of the most notable was Novartis’ disastrous Aviva Life range of functional foods and beverages, which was pulled from the market within three years.

Another was Johnson & Johnson-owned McNeil’s failure in cholesterol-lowering foods. McNeil mistakenly believed that a cholesterol-lowering food - Benecol - backed by multiple clinical studies and carrying an approved health claim could become a mass market success.

McNeil invested around $100 million (€79m) in a US market launch. The launch got sales of $30 million (€24m). McNeil probably never got a return on its investment and the license was sold back to brand owner, Raisio.

Still, pharma companies believe that they have competitive advantages in functional foods. Here are the two common beliefs:

1. Science


This is what we have heard pharma execs say:

“Drug companies have unmatched research capabilities – this matters particularly in Europe, where the European Food Safety Authority (EFSA) requires a standard of proof that is close to that required for drugs. It will matter more in the US also.”

“Drug companies have vastly more and superior experience in, and knowledge of, how to conduct effective clinical trials.”

2. Regulatory know-how

“Pharma companies have significantly greater expertise than food companies in navigating through regulatory regimes.”

However, if these ever were competitive advantages, they are no-longer. Major food companies already have a track record of creating or buying science that enables them to secure health claims.

One example is Mondelez Belvita Breakfast Biscuits – one of the most successful brands of recent years. Supported by over 20 clinical studies, it has secured a health claim approval for a “sustained energy”​ benefit.


And science is an accessible commodity:

  • There are tens, even hundreds, of universities and research organisations offering their services to the food and beverage industry. They undertake clinical studies and help build dossiers of evidence.
  • Increasingly companies collaborate with a wide range of third party researchers to conduct research that would in the past have been conducted in-house.
  • Research is often a service provided to food and beverage brands by their ingredient suppliers, who deliver not only ingredients but proof of efficacy and validity of claims, final product concepts and formulations and regulatory advice. Such companies range from the large to the small, from Beneo (a major supplier of dietary fibres) to Carbery (a mid-size Irish supplier of dairy proteins).

Competitive disadvantages

Mellentin: Food-curious pharma firms are struggling to match start-ups in functional food innovation

In fact, pharma companies have several competitive disadvantages:

  1. Pharma companies mostly do not own food brands with health credentials that are valid in the mind of the consumer.
  2. They could buy such brands, but they would need to be run at arms-length if they are not to be smothered by the corporate culture.
  3. Or they can launch new brands. But this is high risk, the growth curve is very low and the long wait for breakeven and a positive ROI is more than most pharma companies realise.
  4. Competing food and beverage companies are often world-class at functional foods. One example is New Zealand dairy group Fonterra. Its high-calcium milk brand Anlene is a clinically-proven product that actually works, backed by a sophisticated, focused, consumer communication effort. As a result the brand has retail sales in Asia in excess of $600 million (€478m) and a 50% share of the high-calcium milk market in many countries - despite selling at a 100% price premium.
  5. Fragmented markets, filled with an ever-greater proliferation of niches and a host of dynamic, start-up brands that are close to the consumer, may be the biggest challenge to lumbering giants such as pharma companies.

It’s often claimed that pharma companies can be a force in functional foods. That’s not going to happen. Their track-record – with one or two exceptions - is largely one of failure. If you want to see the future of functional food, look down at the small entrepreneurial brands, operating under the radar, not up at pharma giants.

Julian Mellentin is a food industry consultant, analyst and editor.

Related news

Show more

Related products

show more

Optimize Nutritional Value with DuraLipo™

Optimize Nutritional Value with DuraLipo™

Content provided by INNOBIO Corporation Limited | 02-May-2024 | White Paper

INNOBIO's DuraLipo™ products encapsulates active ingredients within phospholipids, forming a genuine phospholipid bilayer structure.

HRB probiotics in the HMO era

HRB probiotics in the HMO era

Content provided by Morinaga Milk Industry Co., Ltd. | 29-Apr-2024 | White Paper

Discover the science behind human-residential bifidobacteria (HRB) probiotics and their superior benefits for infants.

Related suppliers


Thank you for your comment!

Posted by Julian Mellentin,

That is an interesting point. I hadn't thought of that.

Report abuse

Excellent analysis

Posted by Venki Hariharan,

The article has a lot of substances. The analysis is factual. But I feel that the big pharma companies have prescription generation from doctors and they focus on this. When the results don't come immediately they tend to lose interest and the priority becomes low. I have seen this trend with many big pharma companies in India and Indonesia.

Report abuse

Follow us


View more